Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q1)Sep 30, 2025 | (FY)Jun 30, 2025 | (Q4)Jun 30, 2025 | (Q3)Mar 31, 2025 | (Q2)Dec 31, 2024 | (Q1)Sep 30, 2024 | (FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow (Indirect Method) | ||||||||||
| Cash from operating activities | -33.46%2.55M | 30.03%11.85M | -35.78%2.9M | -29.44%1.93M | 165.20%3.19M | 481.31%3.83M | 317.67%9.11M | 269.17%4.51M | 258.32%2.73M | -20.48%1.2M |
| Net profit before non-cash adjustment | -14.75%2.54M | 86.61%9.23M | 7.54%1.57M | 62.13%1.8M | 158.72%2.88M | 136.00%2.98M | 47.35%4.95M | 245.46%1.46M | 78.01%1.11M | -14.20%1.11M |
| Total adjustment of non-cash items | 50.27%281K | 48.06%1.92M | 36.43%1.06M | 61.98%196K | -12.24%473K | 230.77%187K | 144.15%1.3M | 87.74%778.06K | 160.20%121K | 549.17%539K |
| -Depreciation and amortization | 8.42%1.08M | 37.02%4.73M | 68.73%1.81M | 32.84%979K | -9.95%941K | 67.45%998K | 63.35%3.45M | 107.71%1.07M | 40.65%737K | 97.92%1.05M |
| -Reversal of impairment losses recognized in profit and loss | ---- | ---- | ---- | ---- | ---- | ---- | --0 | --0 | ---- | ---- |
| -Disposal profit | 6.58%-227K | -355.30%-873.03K | ---- | ---- | ---- | ---243K | -122.79%-191.75K | 184.88%2.5M | ---- | ---- |
| -Other non-cash items | -1.06%-574K | 1.33%-1.94M | 220.15%124K | -27.11%-783K | -40.51%-711K | 23.14%-568K | 15.27%-1.96M | 88.33%-103.21K | 9.28%-616K | 21.91%-506K |
| Changes in working capital | -142.60%-279K | -75.60%700.35K | -88.26%267.35K | -104.32%-65K | 64.88%-157K | 241.47%655K | 268.33%2.87M | 209.48%2.28M | 341.06%1.5M | -232.25%-447K |
| -Change in receivables | -163.40%-123K | -85.22%372.73K | -85.24%287.73K | -102.16%-28K | 51.50%-81K | 134.95%194K | 215.04%2.52M | 198.62%1.95M | 513.42%1.29M | -279.55%-167K |
| -Change in inventory | -196.15%-25K | -359.80%-235.1K | -197.51%-108.1K | 42.57%-58K | -25.00%-95K | 73.33%26K | -159.02%-51.13K | 71.51%110.87K | -304.00%-101K | -300.00%-76K |
| -Change in payables | -130.11%-131K | 40.71%562.72K | -59.37%87.72K | -93.25%21K | 109.31%19K | 464.94%435K | -0.01%399.91K | 229.25%215.91K | -54.20%311K | -159.30%-204K |
| Dividends paid (cash flow from operating activities) | ||||||||||
| Dividends received (cash flow from operating activities) | ||||||||||
| Interest paid (cash flow from operating activities) | ||||||||||
| Interest received (cash flow from operating activities) | ||||||||||
| Tax refund paid | -88.42%-797K | -57.94%-2.8M | -29.42%-883.43K | -149.53%-1.07M | -59.25%-422K | -7.09%-423K | 25.42%-1.77M | -26.65%-682.6K | 24.51%-428K | 12.25%-265K |
| Other operating cash inflow (outflow) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating cash flow | -48.62%1.75M | 23.29%9.05M | -47.39%2.02M | -62.66%861K | 195.10%2.77M | 1,193.54%3.4M | 3,910.03%7.34M | 219.47%3.83M | 1,076.53%2.31M | -22.52%939K |
| Investing cash flow | ||||||||||
| Net PPE purchase and sale | 0.65%-770K | 90.63%-3.19M | 71.43%-970.79K | 97.41%-748K | -1.61%-693K | 23.19%-775K | -1,055.52%-34M | -515.25%-3.4M | -3,083.92%-28.91M | 6.70%-682K |
| Net business purchase and sale | ---- | --0 | ---- | ---- | --0 | --0 | --0 | --27.28M | --0 | --0 |
| Net investment property transactions | ---- | ---- | ---- | ---- | ---- | ---- | --0 | --0 | ---- | ---- |
| Net investment product transactions | 107.16%1.87M | -907.79%-27.82M | 87.38%-389.35K | 19.27%-1.16M | -103.39%-200K | -528.95%-26.07M | -116.59%-2.76M | -1,605.34%-3.08M | -90.43%-1.43M | -77.50%5.9M |
| Repayment of advance payments to other parties and cash income from loans | ---- | ---- | ---- | ---- | ---- | ---- | --32.94K | ---- | ---- | ---- |
| Dividends received (cash flow from investment activities) | -6.58%227K | 3.31%972.89K | ---- | ---- | ---- | --243K | --941.75K | ---- | ---- | ---- |
| Interest received (cash flow from investment activities) | 114.50%843K | -14.00%1.45M | -10,350.48%-263.98K | 38.45%839K | -1.65%478K | -33.61%393K | -40.16%1.68M | -100.27%-2.53K | -36.28%606K | -15.48%486K |
| Net changes in other investments | ---- | 6.95%35.23K | ---- | ---- | ---- | ---- | --32.94K | ---- | ---- | ---- |
| Investing cash flow | 108.27%2.17M | 16.29%-28.55M | 88.82%-616K | 56.69%-1.07M | -111.53%-658K | 17.68%-26.21M | -307.13%-34.1M | -2,960.35%-5.51M | -246.83%-2.46M | -78.08%5.71M |
| Financing cash flow | ||||||||||
| Net common stock issuance | ---- | ---- | ---- | ---- | ---- | ---- | --0 | --0 | ---- | ---- |
| Increase or decrease of lease financing | 0.00%-54K | -39.60%-213K | -0.83%-51K | -58.82%-54K | -58.82%-54K | -58.82%-54K | -11.95%-152.58K | -47.48%-50.58K | 0.00%-34K | 0.00%-34K |
| Cash dividends paid | ---- | 0.00%-3.82M | -201.49%-478 | ---- | ---- | ---- | 27.28%-3.82M | 296.25%471 | ---- | ---- |
| Financing cash flow | 0.00%-54K | -1.52%-4.04M | -2.73%-51.48K | -0.49%-3.88M | -58.82%-54K | -58.82%-54K | -125.32%-3.98M | -45.60%-50.11K | 27.09%-3.86M | 0.00%-34K |
| Net cash flow | ||||||||||
| Beginning cash position | -36.88%40.27M | -32.51%63.81M | -40.61%38.92M | -38.16%43M | -34.94%40.94M | -32.51%63.81M | 51.09%94.54M | -32.85%65.53M | -32.74%69.54M | -17.40%62.93M |
| Current changes in cash | 116.89%3.86M | 23.44%-23.53M | 178.03%1.35M | -1.75%-4.08M | -68.85%2.06M | 27.68%-22.86M | -196.15%-30.74M | 43.33%-1.73M | 30.90%-4.01M | -75.70%6.61M |
| End cash Position | 7.79%44.13M | -36.88%40.27M | -36.88%40.27M | -40.61%38.92M | -38.16%43M | -34.94%40.94M | -32.51%63.81M | -32.51%63.81M | -32.85%65.53M | -32.74%69.54M |
| Free cash flow | -62.77%978K | 121.99%5.86M | 140.90%1.05M | 100.42%113K | 708.56%2.08M | 452.14%2.63M | -734.23%-26.66M | 111.54%433.84K | -3,346.11%-26.6M | -46.57%257K |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.